Indometacin farnesil
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | To indometacin |
Elimination half-life | 1.5 hours |
Excretion | Renal |
Identifiers | |
| |
JSmol) | |
| |
| |
(verify) |
Indometacin farnesil (
INN) is a prodrug of the nonsteroidal anti-inflammatory drug (NSAID) indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia
, under the trade names Infree and Dialon, respectively.
External links
- Infree (indometacin farnesil capsules) Full Prescribing Information Archived 2010-12-03 at the Eisai Co.